NCAA Tournament fields to remain at 68 teams in 2026, but future growth is possible
'Expanding the tournament fields is no longer being contemplated for the 2026 men's and women's basketball championships," Dan Gavitt, NCAA senior vice president of basketball, said in a statement on Monday. "However, the committees will continue conversations on whether to recommend expanding to 72 or 76 teams in advance of the 2027 championships.'
NCAA President Charlie Baker has said adding teams could add value to the tournament, and he said the NCAA already has had 'good conversations' with TV partners CBS and Warner Bros., whose deal runs through 2032 at the cost of around $1.1 billion a year.
___
AP college basketball: https://apnews.com/hub/ap-top-25-college-basketball-poll and https://apnews.com/hub/college-basketball
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Zepp Health Corp (ZEPP) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic Product ...
Revenue: $59.4 million, a 46% year-over-year increase. Gross Margin: 36.2%, consistent with Q1 2025 but slightly down year-over-year. Operating Costs: $26 million, compared to $25 million in Q2 2024 and $32 million last quarter. R&D Expenses: $11.2 million, a 3.1% year-over-year increase. Selling and Marketing Expenses: $12 million, a 14.2% year-over-year increase and a 12.9% decrease quarter-over-quarter. G&A Expenses: $4.4 million, compared to $4.9 million in Q2 2024. Adjusted Operating Loss: $4.9 million, a 42% improvement compared to last year. Cash Balance: $95 million as of June 30, down from $103 million in Q1 2025. Debt Reduction: Cumulative retirement of $68.0 million of debt since Q1 2023. Q3 2025 Revenue Outlook: Expected to be between $72 million and $76 million, representing 70% to 79% year-over-year growth. Warning! GuruFocus has detected 7 Warning Signs with ZEPP. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Zepp Health Corp (NYSE:ZEPP) achieved a 46% year-over-year increase in revenue, reaching $59.4 million, marking the first quarter of year-over-year revenue growth since Q2 2021. The T-Rex smartwatch maintained competitive edge with sustained volume growth, setting new standards in the premium outdoor smartwatch category. The Helio Strap, a screen-free fitness tracker, received extensive praise for its accuracy and affordability, tapping into a new market niche. Zepp OS 5.0, powered by AI, achieved substantial advancements in functionality and performance, enhancing user experience. The company successfully mitigated tariff impacts through a flexible supply chain and multi-region sourcing strategy, enhancing operational resilience. Negative Points Gross margin was slightly down year-over-year due to a higher revenue proportion of lower-margin entry-level products. Operating costs increased slightly to $26 million compared to $25 million in Q2 2024, despite efforts to reduce expenses. The company experienced supply constraints with the Helio Strap, impacting potential sales growth. Cash balance decreased from $103 million in Q1 2025 to $95 million as of June 30, 2025, influenced by timing and operating performance factors. The company continues to face challenges from evolving tariff policies and global wearable technology trends. Q & A Highlights Q: Could you please give more color on the recent spike in share price drivers? A: Leon Cheng Deng, CFO: The recent share price increase is due to several factors. Our products are well-received, and our brand is gaining recognition, as evidenced by our successful Amazon Day. Additionally, the market is undergoing a value discovery phase, recognizing that smart hardware companies like ours are gaining market share. We believe our company is undervalued compared to peers, and as we continue executing our strategy, we expect continued growth and value revaluation. Q: How many more product launches are planned for the second half of the year compared to the first half? A: Leon Cheng Deng, CFO: In the first half, we launched entry-level products like Bip 6 and Active 2, and mid-tier products like Balance 2 and Helio Strap. We have exciting products in the pipeline for Q3 and Q4, which will be on par with or exceed the number of launches in the second half of the previous year. Q: Do you expect gross margins to improve in the coming quarters, potentially reaching closer to 40% for the full year? A: Leon Cheng Deng, CFO: While we don't guide on gross margins, we expect them to expand in the second half of the year due to a full quarter of sales from Balance 2 and Helio Strap, along with new product launches. The product mix will likely improve, leading to higher gross margins. Q: What percent of your imports to the USA come from Vietnam, and what are the current tariffs for Chinese and Vietnam production? A: Leon Cheng Deng, CFO: Products shipped from China to the USA face tariffs just south of 25%, while those from Vietnam have close to zero tariffs due to waivers. We aim to ship as much as possible from Vietnam to mitigate tariff impacts, and our efforts have been better than expected. Q: What kind of sales contribution do you expect from the new Helio Strap launch, and what gross margin does it carry? A: Leon Cheng Deng, CFO: The Helio Strap, launched in June, has been well-received and carries a healthy gross margin on par with the company's overall margin. It is priced at $99 and is gaining popularity, with supply constraints being addressed to meet demand. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Freshpet Inc (FRPT) Q2 2025 Earnings Call Highlights: Strong Digital Sales and Margin ...
Net Sales: $264.7 million, up 12.5% year-over-year. Adjusted Gross Margin: 46.9%, compared to 45.9% in the prior year period. Adjusted EBITDA: $44.4 million, up approximately 26% year-over-year. Capital Expenditures: $33.4 million for the second quarter; projected to be approximately $175 million for 2025. Cash on Hand: $243.7 million at the end of the quarter. Store Locations: Products in 29,141 stores, with 24% having multiple fridges. Fridges: 37,985 fridges, more than 2 million cubic feet of retail space. Household Penetration: 14.4 million households, up 11% year-over-year. Digital Sales: Account for 13% of total sales, up 40% in the second quarter. Revised 2025 Guidance: Net sales growth of 13% to 16%; adjusted EBITDA of $190 million to $210 million. Warning! GuruFocus has detected 4 Warning Signs with FRPT. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Freshpet Inc (NASDAQ:FRPT) continues to outperform the subdued dog food category, demonstrating strong growth against economic constraints. Operational improvements have led to a significant increase in adjusted gross margin, with Ennis becoming the most profitable plant sooner than expected. The development of new production technologies is expected to enhance product quality and reduce costs, potentially narrowing the margin gap between different product lines. Freshpet Inc (NASDAQ:FRPT) has successfully reduced capital expenditures by at least $100 million for 2025 and 2026, improving cash flow and reducing capital intensity. Digital sales have grown by 40% in the second quarter, now accounting for 13% of total sales, indicating strong performance in e-commerce channels. Negative Points Freshpet Inc (NASDAQ:FRPT) has adjusted its net sales growth guidance for 2025 from 15%-18% to 13%-16% due to macroeconomic challenges. The company has removed its $1.8 billion net sales target for 2027, citing a reduction in category growth rate and new pet additions. Household penetration growth has slowed, impacting the buy rate and raising concerns about market saturation in the premium dog food segment. Economic factors such as return-to-office mandates and high housing costs are negatively affecting consumer behavior, leading to deferred pet ownership and spending. Despite operational efficiencies, the company faces challenges in reaccelerating net sales growth amidst a competitive market and economic uncertainty. Q & A Highlights Q: Can you elaborate on the path to achieving a 22% EBITDA margin by 2027, particularly regarding SG&A and the impact of new technologies? A: Todd Cunfer, CFO: As long as we maintain mid-teens growth, we are confident in achieving the 48% gross margin and 22% EBITDA margin. We expect significant G&A leverage and potential upside from new technologies. Media spending will likely grow with sales, but the main upside is in gross margin and SG&A leverage. Q: Why did you remove the net sales target but maintain the margin targets? A: Todd Cunfer, CFO: Achieving the 22% EBITDA margin requires low to mid-teens growth. If growth slows to 10% or lower, reaching 22% would be challenging due to lack of G&A leverage. We are confident in maintaining double-digit growth, but specific guidance will be provided later. Q: How are household penetration and buy rate trends affecting your business? A: Billy Cyr, CEO: The buy rate is currently above our long-term growth rate due to slower household penetration growth. Consumers are hesitant to trade up, impacting both new customer acquisition and existing customer spending. However, our premium product, Home Style Creations, is growing rapidly, indicating some consumers are still willing to trade up. Q: What is your outlook on household penetration and the potential ceiling for premium dog food consumers? A: Nicki Baty, COO: We believe there is significant runway for growth, with a total addressable market goal in the mid-30s million households. We are targeting MVPs (most valuable pet parents) and aim to grow from 2 million to 7 million MVPs, indicating strong potential for future growth. Q: How are you planning to drive demand in the second half of the year, and what role will value-focused products play? A: Billy Cyr, CEO: We will focus on advertising with a new message, expanded distribution, and product innovation. The new complete nutrition bag product will launch in September/October, primarily driving household penetration. The main drivers will be advertising and retail availability expansions. Q: How do you view the competitive landscape, particularly with Blue Buffalo's entry into the fresh segment? A: Billy Cyr, CEO: Blue Buffalo's entry validates the fresh segment's potential. Historically, category creators like us tend to capture the lion's share. Increased competition and advertising will likely grow the category, benefiting all players. We feel confident in our competitive position and expect increased awareness to drive growth. Q: Can you provide more details on the shift in shipments from Q2 to Q3 and the impact on CapEx? A: Todd Cunfer, CFO: We saw a $3-4 million shift from June to July, confirmed by strong July sales. Regarding CapEx, the $100 million reduction over the next two years is due to both lower demand and improved efficiencies. The delay in Phase III of Ennis is a significant factor, enabled by operational improvements. Q: How are economic factors like return-to-office and housing costs affecting pet ownership trends? A: Billy Cyr, CEO: Economic factors have slowed new pet additions, particularly among younger generations. While high-income baby boomers may not replace pets, younger generations face barriers like housing costs. These trends are cyclical, and we expect a return to more normalized growth rates over time. Q: Are there plans to expand the cat food offering given current market trends? A: Billy Cyr, CEO: We are interested in the growing cat food market, but it requires different product requirements and distribution strategies. We have a small cat food business and are exploring opportunities, but significant expansion is not imminent. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
23 minutes ago
- Yahoo
Hims & Hers Health Inc (HIMS) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amid ...
Revenue: $545 million, a 73% year-over-year increase. Adjusted EBITDA Margin: Over 15%. Subscribers: Increased by 73,000 quarter over quarter to over 2.4 million, a 31% year-over-year growth rate. Monthly Average Revenue per Subscriber: Declined quarter over quarter to $74 from $84. Gross Margin: Expanded 3 points quarter over quarter to 76%. Cash and Short-term Investments: Over $1.1 billion at the end of the second quarter. Free Cash Flow: Negative $69 million for the second quarter. Third Quarter Revenue Guidance: Expected between $570 million to $590 million. Full Year Revenue Guidance: Expected between $2.3 billion and $2.4 billion. Full Year Adjusted EBITDA Guidance: Expected between $295 million to $335 million. Warning! GuruFocus has detected 5 Warning Sign with HIMS. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Hims & Hers Health Inc (NYSE:HIMS) reported a 73% year-over-year revenue growth to $545 million in Q2 2025, with an adjusted EBITDA margin exceeding 15%. The company is expanding its platform with new specialties, including hormonal health, which is expected to address significant health issues for both men and women. Hims & Hers Health Inc (NYSE:HIMS) successfully acquired ZAVA, enhancing its presence in the UK and establishing a foundation for further expansion in Europe and Canada. The company is investing in AI and technology to enhance personalized care, aiming to provide 24/7 support and improve patient engagement. Hims & Hers Health Inc (NYSE:HIMS) plans to offer lab testing as a standalone service, which is expected to empower customers with better health insights and proactive health management. Negative Points The company faced headwinds from off-boarding GLP-1 subscribers on commercially available dosages, impacting revenue recognition. There is a decline in the on-demand sexual health subscriber base, which is expected to continue affecting revenue in the short term. Hims & Hers Health Inc (NYSE:HIMS) reported a negative free cash flow of $69 million in Q2 2025 due to significant investments in inventory and working capital. The transition towards more premium daily offerings in the sexual health segment is causing temporary revenue declines. The company anticipates increased marketing and technology investments, which may pressure margins in the near term. Q & A Highlights Q: Why was now the right time to expand internationally, and what made ZAVA the right company to acquire? A: Andrew Dudum, CEO, explained that the acquisition of ZAVA is a strategic move to replicate Hims & Hers' personalized, high-touch, affordable precision medicine model in key international markets. ZAVA's ability to scale in unique regulatory environments was a key factor in the acquisition. The international market is seen as a focused effort, with a multibillion-dollar revenue opportunity in a few key markets. Q: How does the launch of at-home lab testing improve the business and support the broader mission of Hims & Hers? A: Andrew Dudum, CEO, emphasized that at-home lab testing is foundational for transitioning healthcare from treatment to prevention. It simplifies necessary tests, makes them affordable, and educates patients on optimal health metrics. This initiative is expected to open membership opportunities similar to Amazon or Costco, focusing on preventative health. Q: Can you provide insights into the core business dynamics and expectations for Q3, especially regarding the personalized GLP-1 offering? A: Oluyemi Okupe, CFO, noted material headwinds in the GLP-1 segment due to off-boarding commercially available dosages. The core business is experiencing a drag from the sexual health on-demand segment, but specialties like dermatology and weight loss are growing robustly. The transition to daily offerings in sexual health is expected to improve retention and customer lifetime value. Q: What are the expectations for the Canadian expansion and the impact of generic semaglutide pricing? A: Andrew Dudum, CEO, stated that the Canadian expansion will leverage ZAVA's expertise, with offerings under the Hims & Hers brand. The generic semaglutide is expected to be priced significantly lower than branded options, unlocking substantial market access in Canada, where a large portion of the population is affected by weight issues. Q: How is the Hers business performing, and what are the key growth drivers? A: Oluyemi Okupe, CFO, reported robust growth in the Hers business, driven by dermatology, weight loss, and mental health offerings. The upcoming launch of hormonal support for menopause is expected to further catalyze growth. Q: What is the approach to AI investments, and what impact is expected on the business? A: Andrew Dudum, CEO, highlighted a strategy focused on immediate, tactical improvements through AI. The platform's extensive patient interactions allow for rapid deployment of AI use cases, aiming to enhance efficiency and engagement across the provider, patient, and pharmacist interfaces within 3 to 6 months. Q: Can you discuss the marketing strategy and patient acquisition costs for the second half of the year? A: Oluyemi Okupe, CFO, stated that marketing investments will be robust but adhere to a capital allocation framework with a payback period of less than a year. The focus will be on specialty-specific investments and talent acquisition to support new specialties and international expansion. Q: What are the expectations for inventory levels and supply chain management? A: Oluyemi Okupe, CFO, explained that inventory levels increased to ensure a durable supply for new specialties and to leverage the strong balance sheet amid global uncertainties. This is seen as an anomaly, with future inventory adjustments expected to stabilize. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
